[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts",
    "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=5ca4a22023f888ff482bf15951c5461402bb608b475315890c1bbf19afead238",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753307403,
      "headline": "Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts",
      "id": 136062510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=5ca4a22023f888ff482bf15951c5461402bb608b475315890c1bbf19afead238"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada",
    "summary": "Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes, including a reimbursement agreement with NHS England, potentially added positive sentiment to the stock, which saw a 7% rise over the past month. Amidst a generally rising market marked by all-time highs in broader indices like the S&P 500, Vertex's price movement aligns with broader positive...",
    "url": "https://finnhub.io/api/news?id=e26d024bf399d79114742d9e845f3db8dff04ca59bc6091faa0bf25c90f3f033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753291103,
      "headline": "Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada",
      "id": 136062511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes, including a reimbursement agreement with NHS England, potentially added positive sentiment to the stock, which saw a 7% rise over the past month. Amidst a generally rising market marked by all-time highs in broader indices like the S&P 500, Vertex's price movement aligns with broader positive...",
      "url": "https://finnhub.io/api/news?id=e26d024bf399d79114742d9e845f3db8dff04ca59bc6091faa0bf25c90f3f033"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=67b5479ac695dbff03fb43c6ed9f4b7c356b63acb2ebfad04528aa4456dcf0a0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288620,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 136071761,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=67b5479ac695dbff03fb43c6ed9f4b7c356b63acb2ebfad04528aa4456dcf0a0"
    }
  },
  {
    "ts": null,
    "headline": "Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?",
    "summary": "Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
    "url": "https://finnhub.io/api/news?id=cbae552f569e1b2e8896ab4cf5be51a78b7b9363709fe5dfdd00b44614513478",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753279020,
      "headline": "Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?",
      "id": 136062512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
      "url": "https://finnhub.io/api/news?id=cbae552f569e1b2e8896ab4cf5be51a78b7b9363709fe5dfdd00b44614513478"
    }
  },
  {
    "ts": null,
    "headline": "Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big",
    "summary": "Crispr Therapeutics AG stock has soared 90% since May, driven by Casgevy approval and future breakthroughs in gene editing. Click for my CRSP stock update.",
    "url": "https://finnhub.io/api/news?id=d61122e1b8e0ae68b2d8a94d2416a75baa4c95eb66f1d70a148c7e750ac79013",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753268608,
      "headline": "Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big",
      "id": 136045218,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162932737/image_2162932737.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Crispr Therapeutics AG stock has soared 90% since May, driven by Casgevy approval and future breakthroughs in gene editing. Click for my CRSP stock update.",
      "url": "https://finnhub.io/api/news?id=d61122e1b8e0ae68b2d8a94d2416a75baa4c95eb66f1d70a148c7e750ac79013"
    }
  }
]